# Japan Microbiome Sequencing Services Market > Japan Microbiome Sequencing Services Market Research Report: By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) andBy Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 17.84% - **2024:** $ 93.75 Million - **2025:** $ 110.47 Million - **2035:** $ 570.5 Million - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) **Report ID:** MRFR/HS/52147-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/japan-microbiome-sequencing-services-market-53909 --- ## Market Summary ## **Japan Microbiome Sequencing Services Market Overview****:** As per MRFR analysis, the Japan Microbiome Sequencing Services Market Size was estimated at 70.97 (USD Million) in 2023. The Japan Microbiome Sequencing Services Market Industry is expected to grow from 78(USD Million) in 2024 to 386 (USD Million) by 2035. The Japan Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 15.647% during the forecast period (2025 - 2035). ### **Key Japan Microbiome Sequencing Services Market Trends Highlighted** Several substantial trends are currently being observed in the Japan Microbiome Sequencing Services Market, which is being driven by technological advancements and an increasing emphasis on personalized medicine. The Japanese government has been actively promoting research initiatives to improve comprehension of the human microbiome, thereby nurturing collaborations between academia and industry.  This has led to an increased demand for microbiome sequencing services, which are intended to address a variety of health concerns, such as disease prevention and gastrointestinal health. Moreover, the expansion of this market is being facilitated by the emergence of biotechnology companies in Japan, which are utilizing innovative sequencing techniques to conduct more comprehensive and precise microbiome-based analyses. Integration of sequencing data with artificial intelligence and big data analytics to enhance health outcomes is one of the opportunities in the Japan Microbiome Sequencing Services Market. The potential to captivate new segments of consumers who are seeking customized healthcare solutions based on their microbiome profiles is present as more organizations in Japan invest in data-driven healthcare solutions. Furthermore, healthcare providers are being compelled to incorporate microbiome analysis into their standard practices as a result of the growing recognition of the microbiome's relevance to a variety of diseases, including obesity, diabetes, and mental health disorders. In recent years, there has been an increase in the popularity of lifestyle modifications and preventive healthcare, which are encouraged by microbiome insights.Additionally, the demand for microbiome analysis in dietary recommendations is being further bolstered by the growing interest in nutraceuticals that promote digestive health.  The country is positioned as a significant player in the global microbiome sequencing landscape as a result of the focus on research and development in microbiome-related disciplines, which is driven by Japan's robust healthcare system. The Japan Microbiome Sequencing Services Market is on the brink of further expansion, which will be fueled by enhanced consumer awareness and technological innovation, as these trends continue to develop. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Japan Microbiome Sequencing Services Market Drivers** ### **Growing Awareness of the Human Microbiome's Role in Health** In Japan, there is a rapidly increasing awareness among both healthcare professionals and the general public regarding the significance of the human microbiome in health conditions including gastrointestinal diseases, obesity, and immune disorders. According to the Ministry of Health, Labour and Welfare in Japan, approximately 30% of the Japanese population suffers from gastrointestinal issues, which is leading to an intensified focus on the microbiome as a therapeutic target.Furthermore, institutions like the RIKEN Center for Integrative Medical Sciences are driving Research and Development (R&D) initiatives aimed at understanding the microbiome's role in health, thereby propelling the Japan Microbiome Sequencing Services Market Industry. As awareness grows, demand for microbiome sequencing services is expected to surge, contributing significantly to market growth. ### **Advancements in Sequencing Technologies** The advancement in sequencing technologies has made microbiome analysis more accessible and cost-effective in Japan. Innovations such as Next-Generation Sequencing (NGS) are providing accurate and rapid results, attracting both academic and commercial entities. For instance, with the support from the Japan Science and Technology Agency, various public universities are developing state-of-the-art sequencing platforms. This improvement has resulted in a price reduction of microbiome sequencing services by up to 40% over the past five years.Such technological strides are expected to enhance the adoption of microbiome sequencing services in the Japan Microbiome Sequencing Services Market Industry, thereby driving its growth. ### **Rising Demand for Personalized Medicine** The personalized medicine trend is flourishing in Japan, with a growing emphasis on tailored healthcare solutions based on individual genetic and microbiomic profiles. The Japanese government has set forth initiatives promoting personalized medicine as a means to optimize patient care and reduce healthcare costs. According to recent reports, around 60% of Japanese doctors are now considering microbiome data in their treatment decisions. The partnership between Renowned University of Tokyo and various biotech companies is enhancing the research on using microbiome data for patient stratification in treatments, thus spurring growth in the Japan Microbiome Sequencing Services Market Industry. ## **Japan Microbiome Sequencing Services Market Segment Insights****:** ### **Microbiome Sequencing Services Market Technology Insights** The Japan Microbiome Sequencing Services Market within the Technology segment plays a crucial role in advancing genomic research and healthcare solutions. This segment includes various methods such as Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and others, each contributing uniquely to the understanding of microbiomes.  For instance, Short Gun Sequencing is recognized for its comprehensive approach, allowing the analysis of entire genomes, which is vital for accurate microbiome characterization.In contrast, Sequencing by Synthesis (SBS) holds a significant position due to its ability to provide high-throughput sequencing data, making it indispensable for large-scale genomic studies.  Targeted Gene Sequencing focuses on specific areas of interest, thereby expediting discovery in clinical applications by honing in on genes that influence health outcomes. Additionally, RNA Sequencing has gained traction as it offers valuable insights into gene expression patterns, essential for understanding microbial interactions and functions in various environments.This diversity in technological approaches fosters innovation and enhances the overall capabilities of microbiome research in Japan. The continuous evolution of these techniques is driven by advancements in computational tools and bioinformatics, enabling researchers to process and analyze vast amounts of data efficiently. The Japanese government actively supports microbiome research through funding initiatives and collaboration with academic institutions, positioning the country to lead in this burgeoning field. Overall, the significance and interplay of these technological methods highlight the critical opportunities and challenges faced within the Japan Microbiome Sequencing Services Market. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Microbiome Sequencing Services Market Application Insights** The Application segment of the Japan Microbiome Sequencing Services Market plays a crucial role in addressing a variety of health issues and enhancing patient outcomes. With the increasing prevalence of gastrointestinal diseases, there is growing interest in understanding how microbiome composition influences these conditions. Infectious diseases also benefit significantly from microbiome research, as insights gained can lead to better diagnostic and therapeutic approaches. CNS diseases represent another vital area as emerging studies link gut microbiota to neurological health, suggesting new avenues for treatment.Oncology, too, is gaining traction, with research exploring the interplay between the microbiome and cancer therapies, potentially paving the way for personalized medicine. The category of 'Others' encompasses various applications that further underline the market's versatility and the increasing recognition of the microbiome's role in overall health. The rising investment in Research and Development for these applications contributes to the ever-expanding landscape of the Japan Microbiome Sequencing Services Market, indicating significant opportunities for growth and innovation within the industry. ## **Japan Microbiome Sequencing Services Market Key Players and Competitive Insights****:** The Japan Microbiome Sequencing Services Market is characterized by a rapidly evolving landscape as advancements in sequencing technology and a growing understanding of the microbiome's role in health and disease spur increased investment and interest in this field. Within this market, a variety of players range from established biotechnology firms to emerging startups, each seeking to capitalize on the immense potential of microbiome research.  Competitive dynamics are influenced by factors such as technological innovation, research partnerships, and the integration of bioinformatics services. As companies navigate this landscape, they are focused on differentiating their offerings through specialization in service delivery, precision, and comprehensive data analysis, making it essential for stakeholders to remain attuned to shifts in consumer demand and regulatory frameworks.GeneWiz stands out within the Japan Microbiome Sequencing Services Market due to its robust reputation for high-quality sequencing and customer service.  The company offers an extensive range of genomics services, including microbiome analysis, which is vital for understanding the complex interactions within microbial communities. GeneWiz has established significant market presence in Japan, leveraging its advanced technological capabilities and a team of skilled professionals to deliver precise insights.  This strength is complemented by their commitment to innovation and customer support, which has earned them a loyal clientele. Furthermore, GeneWiz maintains strategic collaborations with academic institutions and research organizations in Japan, further enhancing its position and allowing for the continuous evolution of its service offerings in response to market needs.Zymo Research is another key player in the Japan Microbiome Sequencing Services Market, having made considerable strides in providing cutting-edge products and services that facilitate microbiome research.  The company specializes in innovative solutions such as DNA and RNA extraction kits, library preparation kits, and microbial profiling solutions, which cater directly to the requirements of researchers in Japan. Zymo Research's strengths lie in its advanced product suite and a strong focus on enhancing the reproducibility and accuracy of microbial studies, which has resulted in widespread adoption in both academic and clinical settings.  The company's market presence is further reinforced by a series of strategic partnerships and collaborations within Japan’s research community, coupled with efforts to expand its offerings through mergers and acquisitions that align with its mission. Through its commitment to research-driven innovation, Zymo Research is well-positioned as a formidable entity in the growing field of microbiome sequencing. ### **Key Companies in the Japan Microbiome Sequencing Services Market Include:** - GeneWiz - Zymo Research - Fulgent Genetics - Macrogen - BioRad Laboratories - Roche - Qiagen - Eurofins Scientific - Dunlee - Thermo Fisher Scientific - Illumina - Novogene - Agilent Technologies - Microbial Genomics - BGI Genomics ## **Japan Microbiome Sequencing Services Market Industry Developments** Recent developments in the Japan Microbiome Sequencing Services Market include increased investment and growth from various companies as consumer interest in personalized medicine rises. Notably, GeneWiz and Zymo Research have been at the forefront of offering innovative sequencing solutions tailored to the Japanese market demand. In a significant event, Macrogen announced a strategic partnership with Qiagen in July 2023 aimed at expanding their microbiome analysis capabilities in Japan. Additionally, Thermo Fisher Scientific revealed plans in August 2023 to enhance its operational footprint in Japan, reflecting the company's commitment to meet the growing demand for advanced sequencing technologies. The market has seen strong valuation growth due to these advancements, with organizations actively exploring collaborations to leverage genomic data. Over the past two to three years, the demand for microbiome research related to gut health has significantly gained traction in Japan, leading to an increased focus on R&D initiatives. Companies such as Illumina and Eurofins Scientific continue to play essential roles in advancing microbiome sequencing services, indicating a thriving landscape for genetic research and diagnostics in Japan. ## **Japan Microbiome Sequencing Services Market Segmentation Insights** ### **Microbiome Sequencing Services Market Technology****Outlook** - Sequencing by Litigation (SBL) - Sequencing by Synthesis (SBS) - Short Gun Sequencing - Targeted Gene Sequencing - RNA Sequencing - Others ### **Microbiome Sequencing Services Market Application****Outlook** - Gastrointestinal Diseases - Infectious Diseases - CNS Diseases - Oncology - Others ## Market Drivers ### Growing Interest in Gut Health The increasing awareness of gut health among the Japanese population is driving the microbiome sequencing-services market. Consumers are becoming more informed about the role of gut microbiota in overall health, leading to a surge in demand for services that analyze and interpret microbiome data. This trend is reflected in the rising sales of probiotics and functional foods, which are projected to reach ¥500 billion by 2026. As individuals seek personalized insights into their gut health, the microbiome sequencing-services market is likely to expand, catering to both health-conscious consumers and healthcare professionals looking for data-driven solutions. ### Expansion of Research Initiatives Japan's commitment to advancing microbiome research is a significant driver for the microbiome sequencing-services market. Government and private sector investments in research initiatives are fostering innovation and collaboration among academic institutions and biotech companies. For instance, the Japanese government allocated ¥10 billion in 2025 to support microbiome-related research projects. This funding is expected to enhance the understanding of microbiome functions and their implications for health, thereby increasing the demand for sequencing services. As research progresses, the market is likely to see a rise in applications across various fields, including nutrition, pharmaceuticals, and disease prevention. ### Integration of AI in Data Analysis The integration of artificial intelligence (AI) in data analysis is transforming the microbiome sequencing-services market. AI technologies are being utilized to process and interpret complex microbiome data more efficiently, enabling researchers and clinicians to derive actionable insights. In Japan, companies are increasingly adopting AI-driven platforms to enhance their sequencing services, which could lead to improved accuracy and faster turnaround times. This technological advancement may attract more clients, including healthcare providers and research institutions, thereby expanding the market. The potential for AI to revolutionize data interpretation suggests a promising future for the microbiome sequencing-services market. ### Consumer Demand for Health Insights The rising consumer demand for health insights is significantly impacting the microbiome sequencing-services market. Japanese consumers are increasingly seeking personalized health information to optimize their well-being. This trend is evident in the growing popularity of home testing kits and direct-to-consumer sequencing services, which allow individuals to gain insights into their microbiome composition. The market is likely to see an influx of innovative products and services designed to meet this demand, as companies strive to provide accessible and user-friendly solutions. This shift towards consumer-driven health insights may further propel the growth of the microbiome sequencing-services market. ### Rising Prevalence of Chronic Diseases The increasing prevalence of chronic diseases in Japan is a notable driver for the microbiome sequencing-services market. Conditions such as obesity, diabetes, and inflammatory bowel disease are becoming more common, prompting healthcare professionals to explore the role of the microbiome in disease management. As a result, there is a growing demand for sequencing services that can provide insights into the microbiome's influence on these conditions. The market is expected to benefit from collaborations between healthcare providers and sequencing service companies, as they seek to develop targeted interventions based on microbiome analysis. This trend indicates a potential growth trajectory for the market. ## Future Outlook The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) in Japan is projected to grow at a 17.84% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing health awareness, and technological innovations. **New opportunities:** - Development of targeted microbiome therapies for chronic diseases - Integration of AI-driven analytics for enhanced data interpretation - Expansion of subscription-based microbiome testing services for consumers By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in innovative health solutions. ## Segment Insights ### By Technology: SBL (Largest) vs. SBS (Fastest-Growing) In the Japan microbiome sequencing-services market, the segments of Sequencing by Litigation (SBL) and Sequencing by Synthesis (SBS) play pivotal roles in the market's structure. SBL is established as the dominant segment, holding a substantial share of the overall market. In contrast, SBS is positioned as the fastest-growing segment, driven by advancements in technology and increasing applications across various fields such as healthcare and environmental management. The growth trends for these technologies are fueled by a strong demand for accurate and efficient sequencing methods. Innovations in sequencing technology and decreasing costs are promoting the adoption of SBS, while the reliability and comprehensive insights provided by SBL continue to sustain its significant market share. As a result, stakeholders are keenly observing these segments, anticipating shifts that could reshape competitive dynamics in the market. Technology: SBL (Dominant) vs. SBS (Emerging) Sequencing by Litigation (SBL) is characterized by its robust methodologies, ensuring high confidence in genetic sequencing results, which is crucial for various applications like disease diagnosis. As the dominant player, SBL has established a strong reputation for reliability among researchers and healthcare providers in the Japan microbiome sequencing-services market. On the other hand, Sequencing by Synthesis (SBS) is emerging rapidly, marked by its technological advancements that allow for faster sequencing times and lower costs. Its appeal lies in versatility, enabling wide-ranging applications from clinical diagnostics to academic research. Together, these technologies are key components shaping the future of microbiome research and analysis. ### By Application: Gastrointestinal Diseases (Largest) vs. Oncology (Fastest-Growing) The Japan microbiome sequencing-services market is characterized by a diverse range of applications, with Gastrointestinal Diseases being the largest segment. This segment has consistently shown a significant market share due to the rising prevalence of gastrointestinal disorders and an increasing demand for personalized medicine. Following closely, Oncology is emerging as a fast-growing application segment, fueled by advancements in cancer research and an increased focus on targeted therapies. Growth trends in this market are driven by technological advancements in sequencing techniques and the expanding understanding of the microbiome's role in health and disease. As healthcare providers and researchers recognize the potential of microbiome analysis in developing effective therapeutic solutions, the demand for sequencing services is expected to rise, particularly in Oncology applications, which have gained momentum due to innovative treatment strategies and increased funding for related research. Gastrointestinal Diseases (Dominant) vs. Oncology (Emerging) Gastrointestinal Diseases represent the dominant application segment in the Japan microbiome sequencing-services market, appealing to healthcare professionals due to their significant association with gut health and disease management. This segment benefits from an established framework of clinical studies and treatment protocols, leading to widespread adoption of microbiome sequencing technologies. In contrast, Oncology is recognized as an emerging application area, capturing the interest of researchers and clinicians who are exploring the links between the microbiome and cancer immunotherapy. The rapid development of personalized oncology treatments and breakthroughs in sequencing capabilities position this segment for robust growth, creating opportunities for innovative applications and partnerships in the healthcare ecosystem. ## Competitive Benchmarking The microbiome sequencing-services market in Japan is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing awareness of the microbiome's role in health. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Qiagen (DE) are at the forefront, leveraging their extensive research capabilities and innovative technologies to enhance their market positions. Illumina (US) focuses on expanding its product offerings and improving sequencing accuracy, while Thermo Fisher Scientific (US) emphasizes strategic partnerships to broaden its service capabilities. Qiagen (DE) is actively pursuing regional expansion, particularly in Asia, to tap into the growing demand for microbiome analysis. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and collaboration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set industry standards and drive technological advancements. This competitive structure fosters an environment where smaller firms can innovate but also face challenges in scaling their operations to compete effectively. In October Illumina (US) announced a partnership with a leading Japanese research institution to develop advanced microbiome sequencing technologies. This collaboration is expected to enhance Illumina's capabilities in the region and solidify its position as a market leader. The strategic importance of this partnership lies in its potential to accelerate innovation and improve access to cutting-edge sequencing solutions for local researchers and healthcare providers. In September Thermo Fisher Scientific (US) launched a new microbiome analysis platform tailored for clinical applications. This platform aims to provide healthcare professionals with actionable insights into patient health based on microbiome data. The introduction of this platform signifies Thermo Fisher's commitment to integrating microbiome analysis into clinical practice, potentially transforming patient care and diagnostics. In August Qiagen (DE) expanded its product portfolio by acquiring a microbiome-focused startup. This acquisition is likely to enhance Qiagen's technological capabilities and broaden its service offerings in the microbiome space. By integrating innovative solutions from the startup, Qiagen aims to strengthen its competitive edge and respond to the increasing demand for comprehensive microbiome analysis. As of November current trends in the microbiome sequencing-services market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in data analysis. Strategic alliances are becoming increasingly important, as companies seek to combine their strengths to drive innovation and improve service delivery. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to provide comprehensive, actionable insights into microbiome data. ## Recent News & Developments Recent developments in the Japan Microbiome Sequencing Services Market include increased investment and growth from various companies as consumer interest in personalized medicine rises. Notably, GeneWiz and Zymo Research have been at the forefront of offering innovative sequencing solutions tailored to the Japanese market demand. In a significant event, Macrogen announced a strategic partnership with Qiagen in July 2023 aimed at expanding their microbiome analysis capabilities in Japan. Additionally, Thermo Fisher Scientific revealed plans in August 2023 to enhance its operational footprint in Japan, reflecting the company's commitment to meet the growing demand for advanced sequencing technologies. The market has seen strong valuation growth due to these advancements, with organizations actively exploring collaborations to leverage genomic data. Over the past two to three years, the demand for microbiome research related to gut health has significantly gained traction in Japan, leading to an increased focus on R&D initiatives. Companies such as Illumina and Eurofins Scientific continue to play essential roles in advancing microbiome sequencing services, indicating a thriving landscape for genetic research and diagnostics in Japan. ## Report Scope | MARKET SIZE 2024 | 93.75(USD Million) | | --- | --- | | MARKET SIZE 2025 | 110.47(USD Million) | | MARKET SIZE 2035 | 570.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.84% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) | | Segments Covered | Technology, Application | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in microbiome sequencing-services market. | | Key Market Dynamics | Rising demand for personalized medicine drives innovation in microbiome sequencing-services, enhancing competitive dynamics in Japan. | | Countries Covered | Japan | ## Frequently Asked Questions **Q: What is the current valuation of the microbiome sequencing-services market in Japan?** A: The market was valued at $93.75 Million in 2024. **Q: What is the projected market valuation for the microbiome sequencing-services market in Japan by 2035?** A: The market is projected to reach $570.5 Million by 2035. **Q: What is the expected CAGR for the Japan microbiome sequencing-services market during the forecast period 2025 - 2035?** A: The expected CAGR is 17.84% during the forecast period. **Q: Which companies are the key players in the Japan microbiome sequencing-services market?** A: Key players include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, Genomatix, Microbiome Insights, Second Genome, and CosmosID. **Q: What are the main technology segments in the Japan microbiome sequencing-services market?** A: Main technology segments include Sequencing by Litigation, Sequencing by Synthesis, Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and Others. **Q: What is the valuation range for Sequencing by Synthesis in the Japan microbiome sequencing-services market?** A: The valuation range for Sequencing by Synthesis is $20.0 Million to $120.0 Million. **Q: Which application segment has the highest valuation in the Japan microbiome sequencing-services market?** A: The Gastrointestinal Diseases segment has the highest valuation, ranging from $30.0 Million to $180.0 Million. **Q: What is the valuation range for Oncology in the Japan microbiome sequencing-services market?** A: The valuation range for Oncology is $20.0 Million to $120.0 Million. **Q: How does the valuation of Infectious Diseases compare to CNS Diseases in the Japan microbiome sequencing-services market?** A: Infectious Diseases has a valuation range of $25.0 Million to $150.0 Million, whereas CNS Diseases ranges from $15.0 Million to $90.0 Million. **Q: What is the projected growth trend for the Japan microbiome sequencing-services market?** A: The market is expected to experience substantial growth, driven by advancements in technology and increasing applications in healthcare. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-microbiome-sequencing-services-market-53909*